The Relative Strength (RS) Rating for McKesson (MCK) stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.
↑ XThis exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their biggest runs. See if McKesson stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
McKesson stock is trying to complete a cup without handle with a 637.51 buy point. See if it medical stock can break out in heavy trading.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 13%, compared to 8% in the prior report. Revenue increased from 6% to 21%.
McKesson stock holds the No. 3 rank among its peers in the Medical-Wholesale Drugs industry group. Cencora (COR) is the top-ranked stock within the group.
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。